Zevra Therapeutics (ZVRA) has wrapped up FY 2025 with Q4 total revenue of US$34.1 million and basic EPS of US$0.21, while trailing twelve month figures show total revenue of US$106.5 million and basic EPS of US$1.40. Over the past year, the company has seen total revenue move from US$23.6 million on a trailing basis in Q4 2024 to US$106.5 million by Q4 2025, alongside a shift from a trailing net loss of US$105.5 million to trailing net income of US$77.6 million. This sets the stage for a more margin focused read of the latest quarter.

See our full analysis for Zevra Therapeutics.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the widely followed growth and risk narratives around Zevra, and where the fresh data may challenge those stories.

FY 2025 swing to US$77.6m trailing profit puts rare disease model in focus

• On a trailing twelve month basis, Zevra moved from a net loss of US$105.5 million in Q4 2024 to net income of US$77.6 million by Q4 2025, with total revenue over the same window at US$106.5 million.
• Bulls point to this pivot as evidence that the rare disease portfolio can scale earnings, yet the data also include large non cash items, so:
  • Supportive for the bullish view, trailing basic EPS shifted from a loss of US$2.28 to a profit of US$1.40 while reported revenue growth over the last 12 months is about 24.7% a year.
  • At the same time, the high non cash component flagged in the risk data means this profit mix is exactly what cautious investors watch when they question how durable that US$77.6 million net income really is.

If you are weighing that profit swing against the long term rare disease story, it is worth seeing how bullish investors join the dots between these numbers and their upside case for Zevra: 🐂 Zevra Therapeutics Bull Case

P/E of 8.4x versus peers and DCF fair value of US$72.87 highlight valuation gap

• The shares trade on a trailing P/E of 8.4x against 18.5x for the broader US Pharmaceuticals industry and 10.7x for peers, while a stated DCF fair value of US$72.87 sits well above the current share price of US$11.06.
• Consensus narrative sees this mix of lower multiples and higher modeled value as part of a value growth story, yet the filings add some nuance:
  • On the one hand, analysts in the dataset collectively look for earnings to grow around 28% a year with revenue around 24.7% a year, which lines up with a lower P/E than the industry if that growth is delivered.
  • On the other, the same analysis flags earnings quality as a major risk because a significant portion of profit is non cash, which can matter a lot when you are trying to judge whether an 8.4x P/E and the DCF fair value of US$72.87 are supported by future cash flows.

Quarterly swings show PRV and impairment effects behind the 2025 headline

• Within FY 2025, net income excluding extra items moved from a loss of US$3.1 million in Q1 to income of US$69.4 million in Q2, then a small loss of US$0.5 million in Q3 and income of US$11.8 million in Q4, while quarterly revenue ranged between US$20.4 million and US$34.1 million.
• Bears argue that these uneven quarterly outcomes, plus items like the US$58.7 million OLPRUVA intangible impairment and US$11.7 million inventory write down cited in the narrative, show how dependent results can be on one off or concentrated product moves:
  • That view fits with the pattern that Q2 2025 carried the bulk of annual profit at US$69.4 million, while the other three quarters together added only US$8.7 million of net income excluding extra items.
  • It also lines up with concerns that slow OLPRUVA uptake and small ultra rare patient pools, such as Niemann Pick C, may keep earnings more volatile from quarter to quarter than the full year headline suggests.

If you are more aligned with the cautious take and want to see how skeptics frame these swings, it helps to read the detailed bear case around Zevra’s rare disease exposure and portfolio mix: 🐻 Zevra Therapeutics Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Zevra Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of optimism and caution running through this update, now is a good time to review the numbers yourself and pressure test the story, starting with 5 key rewards and 1 important warning sign.

See What Else Is Out There

Zevra’s earnings story leans heavily on non cash items and uneven quarterly results, which leaves big question marks around how reliable the profit profile really is.

If that volatility makes you uneasy, it is worth balancing your research with 68 resilient stocks with low risk scores, so you can quickly zero in on companies that score better on stability and risk today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.